67-Year-Old Man Presents With Hematuria & Kidney Mass

Data from LITESPARK-005 establish belzutifan as a treatment option in advanced RCC following prior immune checkpoint and antiangiogenic therapies.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

“This is currently the largest pooled safety dataset for a HIF-2α inhibitor we need to be familiar with,” lead study author Toni K. Choueiri, MD.

Various immunotherapy/TKI regimens were observed to determine the impact on survival in patients with metastatic renal cell carcinoma.